Brokerages expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report sales of $1.35 billion for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $1.27 billion to $1.45 billion. Alexion Pharmaceuticals posted sales of $1.14 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 18.4%. The company is scheduled to report its next earnings report on Thursday, April 23rd.

On average, analysts expect that Alexion Pharmaceuticals will report full-year sales of $5.63 billion for the current fiscal year, with estimates ranging from $5.53 billion to $6.11 billion. For the next financial year, analysts expect that the company will post sales of $6.17 billion, with estimates ranging from $5.32 billion to $7.02 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, January 30th. The biopharmaceutical company reported $2.71 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.60 by $0.11. Alexion Pharmaceuticals had a return on equity of 21.29% and a net margin of 48.17%. The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the firm earned $2.14 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 22.7% compared to the same quarter last year.

ALXN has been the subject of several research analyst reports. William Blair reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, January 14th. Cowen reiterated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Thursday, January 30th. SunTrust Banks boosted their price objective on Alexion Pharmaceuticals to $141.00 and gave the company a “buy” rating in a research report on Friday, January 31st. They noted that the move was a valuation call. Morgan Stanley boosted their price objective on Alexion Pharmaceuticals from $128.00 to $131.00 and gave the company an “equal weight” rating in a research report on Friday, January 17th. Finally, Evercore ISI reiterated a “buy” rating and issued a $145.00 price objective on shares of Alexion Pharmaceuticals in a research report on Sunday, November 17th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $149.80.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. New York State Teachers Retirement System raised its stake in shares of Alexion Pharmaceuticals by 0.4% during the 3rd quarter. New York State Teachers Retirement System now owns 311,593 shares of the biopharmaceutical company’s stock worth $30,517,000 after purchasing an additional 1,199 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Alexion Pharmaceuticals by 148.6% during the 3rd quarter. SG Americas Securities LLC now owns 49,669 shares of the biopharmaceutical company’s stock worth $4,865,000 after purchasing an additional 29,691 shares in the last quarter. Man Group plc raised its stake in shares of Alexion Pharmaceuticals by 347.3% during the 3rd quarter. Man Group plc now owns 513,104 shares of the biopharmaceutical company’s stock worth $50,254,000 after purchasing an additional 398,394 shares in the last quarter. Chicago Equity Partners LLC raised its stake in Alexion Pharmaceuticals by 646.8% in the 3rd quarter. Chicago Equity Partners LLC now owns 16,580 shares of the biopharmaceutical company’s stock valued at $1,624,000 after acquiring an additional 14,360 shares during the period. Finally, Janney Montgomery Scott LLC raised its stake in Alexion Pharmaceuticals by 50.2% in the 3rd quarter. Janney Montgomery Scott LLC now owns 34,129 shares of the biopharmaceutical company’s stock valued at $3,343,000 after acquiring an additional 11,408 shares during the period. Hedge funds and other institutional investors own 91.35% of the company’s stock.

Shares of ALXN traded down $0.86 on Tuesday, hitting $102.56. The company’s stock had a trading volume of 1,577,910 shares, compared to its average volume of 1,973,748. The company has a quick ratio of 3.73, a current ratio of 4.25 and a debt-to-equity ratio of 0.23. The firm’s fifty day moving average price is $106.86 and its 200-day moving average price is $107.37. Alexion Pharmaceuticals has a fifty-two week low of $94.59 and a fifty-two week high of $141.86. The firm has a market capitalization of $22.68 billion, a price-to-earnings ratio of 9.56, a P/E/G ratio of 0.87 and a beta of 1.68.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: S&P 500 Index

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.